



Press Release – For immediate release
September 6, 2017 – 05:45pm CEST

Median Technologies to attend the ESMO 2017 Congress, September 8-12, 2017, Madrid, Spain

Sophia Antipolis, France – September 6, 2017 - Median Technologies, the Imaging Phenomics Company®, announced today that it will be exhibiting at the ESMO 2017 Congress, September 8-12 at IFEMA, Feria de Madrid, Spain (exhibition dates: Sept. 8-11).

Median Technologies will share and showcase its imaging solutions and services for clinical trials, featuring both its Lesion Management Solution (LMS) imaging platform and its iBiopsy® platform, at booth #233.

LMS is Median’s legacy imaging platform, a suite of software tools for collecting, analyzing, and managing oncology imaging data with the most advanced algorithms for producing quantitative measurements with various imaging biomarkers. LMS enables automated and standardized detection, quantification and tracking of lesions in 3D medical images.

Median iBiopsy®, or Imaging **B**iomarker **P**henotyping **S**ystem, is Median’s groundbreaking imaging platform that combines non-invasive image biomarkers with phenomics. This unique combination of science and technology is at the very core of precision medicine because it can provide insights into development of novel therapies and individualized treatment strategies. Remarkably, iBiopsy® can measure disease and treatment response without an invasive and costly biopsy.

The ESMO Annual Congress is the Europe’s premier oncology conference, organized by the European Society for Medical Oncology, the largest oncology society in Europe. Each year, the ESMO conference brings together more than 20,000 participants from all around the globe, and is attended by all medical, educational and industrial stakeholders involved in the field of oncology worldwide. More about the ESMO 2017 Congress: <http://www.esmo.org/Conferences/ESMO-2017-Congress>



About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions, LMS for lesion management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need, with an eye on reducing overall care costs. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a US subsidiary in Boston, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA-PME SME equity savings plan setup and has received the label Pass

French Tech Promotion 2016-2017. Median Technologies has been awarded the 2017 Tech 40 Label and has joined the EnterNext Tech 40 Index. Median is a member of the Bpifrance Excellence Network. More information: www.mediantechnologies.com



Contacts

Median Technologies Fredrik Brag, CEO +33 4 92 90 65 82 fredrik.brag@mediantechnologies.com	Press - ALIZE RP Caroline Carmagnol / Wendy Rigal + 33 1 44 54 36 66 median@alizerp.com	Investors - ACTIFIN Ghislaine Gasparetto +33 1 56 88 11 11 ggasparetto@actifin.fr
--	---	---